1200 related articles for article (PubMed ID: 31974366)
1. Lupus nephritis.
Anders HJ; Saxena R; Zhao MH; Parodis I; Salmon JE; Mohan C
Nat Rev Dis Primers; 2020 Jan; 6(1):7. PubMed ID: 31974366
[TBL] [Abstract][Full Text] [Related]
2. Update on Lupus Nephritis: Core Curriculum 2020.
Parikh SV; Almaani S; Brodsky S; Rovin BH
Am J Kidney Dis; 2020 Aug; 76(2):265-281. PubMed ID: 32220510
[TBL] [Abstract][Full Text] [Related]
3. Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT
Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219
[TBL] [Abstract][Full Text] [Related]
4. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
5. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Kronbichler A; Neumann I; Mayer G
Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
[TBL] [Abstract][Full Text] [Related]
6. Current status of lupus nephritis.
Jaryal A; Vikrant S
Indian J Med Res; 2017 Feb; 145(2):167-178. PubMed ID: 28639592
[TBL] [Abstract][Full Text] [Related]
7. Lupus nephritis in children.
Gupta KL
Indian J Pediatr; 1999; 66(2):215-23. PubMed ID: 10798064
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents.
Fanouriakis A; Bertsias G; Liapis G; Marinaki S; Papagianni A; Stangou M; Garyfallos A; Lionaki S; Tektonidou MG; Boletis JN; Boumpas DT
Lupus; 2023 Sep; 32(10):1155-1163. PubMed ID: 37499240
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
[TBL] [Abstract][Full Text] [Related]
10. Pauci-immune crescentic glomerulonephritis caused to dilemma in a patient with suspected systemic lupus erythematosus: a case report.
Uysal C; Ketenci Ertas S; Civan M; Akgun H; Kocyigit I
CEN Case Rep; 2024 Jun; 13(3):174-180. PubMed ID: 37837535
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Ruiz-Irastorza G; Danza A; Khamashta M
Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies for lupus nephritis: Current perspectives and future directions.
Jia X; Lu Y; Zheng X; Tang R; Chen W
Chin Med J (Engl); 2024 Jan; 137(1):34-43. PubMed ID: 38057972
[TBL] [Abstract][Full Text] [Related]
13. [Lupus nephritis: up-to-date].
Karras A
Rev Med Interne; 2015 Feb; 36(2):98-106. PubMed ID: 25443980
[TBL] [Abstract][Full Text] [Related]
14. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
Sixdorf U; Bauer H; Märker-Hermann E
Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
[TBL] [Abstract][Full Text] [Related]
15. Towards new avenues in the management of lupus glomerulonephritis.
Mok CC
Nat Rev Rheumatol; 2016 Apr; 12(4):221-34. PubMed ID: 26729459
[TBL] [Abstract][Full Text] [Related]
16. Systemic Lupus Erythematosus: A Review.
Siegel CH; Sammaritano LR
JAMA; 2024 May; 331(17):1480-1491. PubMed ID: 38587826
[TBL] [Abstract][Full Text] [Related]
17. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
18. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
[TBL] [Abstract][Full Text] [Related]
19. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study.
Li C; Zhou ML; Liang DD; Wang JJ; Yang J; Zeng CH; Liu ZH; Zhang HT
BMJ Open; 2017 Jul; 7(7):e015668. PubMed ID: 28756384
[TBL] [Abstract][Full Text] [Related]
20. Treatment of severe lupus nephritis: the new horizon.
Chan TM
Nat Rev Nephrol; 2015 Jan; 11(1):46-61. PubMed ID: 25421826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
